Investors join Inclinix, Inc. with PMG Research Inc. to create global clinical trial site and patient recruitment organization -- Inclinix-PMG Holdings, Inc.

Investors join Inclinix, Inc. with PMG Research Inc. to create global clinical trial site and patient recruitment organization -- Inclinix-PMG Holdings, Inc.

WILMINGTON, N.C., WINSTON-SALEM, N.C. and CHARLOTTE, N.C., June 4, 2012 -- /PRNewswire/ -- A consortium of investors led by Frontier Capital has funded the strategic merger of Inclinix, Inc. with PMG Research Inc., creating a first-of-kind organization for accelerating clinical trial enrollment from beginning to end.  The company will be led by J. Tobin Geatz, President and CEO, and Jeffrey Reiniche, CFO.  "This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," noted Mr. Geatz.  "We will have more than 120 Principal Investigators and 80 study coordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers, provide our customers rapid enrollment locally and worldwide," he continued.  The company will operate in the short term as two divisions.  Current customers, employees and stakeholders should expect the continued high level of quality, service and performance for which both companies are known. More information will be available in the coming weeks.

About PMG Research

PMG Research, Inc. is an Integrated Site Network based in Winston-Salem, NC. The staff and physicians at PMG Research have contributed to the development of numerous medications, medical devices and vaccines. PMG's mission is to provide unparalleled service to their clinical trial participants and pharmaceutical sponsors.

About Inclinix

Inclinix, Inc. specializes in customized Phase I-IV clinical enrollment solutions for pharmaceutical, biotechnology and medical device organizations. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model. 

About Frontier Capital

Frontier Capital is a Charlotte-based growth equity firm focused exclusively on technology-enabled business services. They partner with management teams that can benefit from capital to accelerate growth, fund acquisitions or generate shareholder liquidity. Their investments include both minority and majority ownership positions in high-growth companies and have built an excellent track record of delivering returns to both their investors and management partners.

SOURCE Inclinix, Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.